Of these, KEAP1 was identified as the top hit in lung adenocarcinoma (LUAD) and explained a large proportion (>10%) of variance for multiple immune traits, including interferon pathway, MHC class II expression, and the NK cell signature score. This evidence concerns the gene KEAP1 and lung adenocarcinoma.